Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients.

Authors:
Kelly H; Sokola B; Abboud H.

Journal:
J Neuroimmunol

Publication Year: 2021

DOI:
10.1016/j.jneuroim.2021.577599

PMCID:
PMC8095041

PMID:
34000472

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Neuroimmunol

Abbreviation: J Neuroimmunol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A…
Feizi P; Sharma K; Pasham SR and 4 more (2022) - Transparency Score: 3/6
Myelin oligodendrocyte glycoprotein-IgG associated disorders (MOGAD) following SARS-CoV-2 infection…
Lambe J; McGinley MP; Moss BP and 5 more (2022) - Transparency Score: 1/6
A case of longitudinally extensive transverse myelitis following vaccination against Covid-19.
Pagenkopf C; Südmeyer M. (2021) - Transparency Score: 2/6
A systematic review of cases of CNS demyelination following COVID-19 vaccination.
Ismail II; Salama S. (2021) - Transparency Score: 3/6
Complex movement disorders in SARS-CoV-2 infection induced acute disseminated encephalomyelitis.
Ghosh R; Dubey S; Mandal A and 2 more (2021) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of Competing Interest Dr. Abboud is a consultant and speaker for Biogen, Genentech, Bristol Myer Squibb, Alexion, and Viela Bio. He receives research support to conduct clinical trials for Novartis, Genentech, Bristol Myer Squibb, and Sanofi Genzyme. Dr. Sokola has received consulting fees from Alexion. Hannah Kelly has no financial disclosures to report."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025